Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTXNYSE:GSKNYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$98.76+0.5%$103.10$76.53▼$131.49$23.70B1.07857,374 shs723,188 shsGSKGSK$35.92+1.5%$37.44$31.72▼$45.93$72.98B0.564.64 million shs4.81 million shsJNJJohnson & Johnson$157.42+2.3%$159.47$140.68▼$169.99$379.37B0.497.96 million shs10.97 million shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech+0.52%+6.06%-0.20%-11.77%+14.31%GSKGSK+1.51%+6.75%-10.98%+7.35%-9.31%JNJJohnson & Johnson+2.26%+5.92%-4.15%+7.07%+8.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNTXBioNTech2.4151 of 5 stars4.42.00.00.02.40.80.0GSKGSK2.8113 of 5 stars2.35.02.50.03.20.01.3JNJJohnson & Johnson4.5199 of 5 stars2.35.04.23.93.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.89Moderate Buy$143.4445.24% UpsideGSKGSK 2.55Moderate Buy$40.5813.00% UpsideJNJJohnson & Johnson 2.56Moderate Buy$171.829.15% UpsideCurrent Analyst Ratings BreakdownLatest JNJ, BNTX, and GSK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025JNJJohnson & JohnsonBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$166.00 ➝ $165.004/16/2025JNJJohnson & JohnsonSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform4/16/2025JNJJohnson & JohnsonRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.004/16/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$164.00 ➝ $169.004/15/2025GSKGSKBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$35.254/14/2025JNJJohnson & JohnsonRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$165.00 ➝ $162.004/10/2025JNJJohnson & JohnsonBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$171.00 ➝ $159.004/9/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$163.00 ➝ $164.004/9/2025JNJJohnson & JohnsonThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$157.00 ➝ $172.004/2/2025JNJJohnson & JohnsonRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.004/2/2025JNJJohnson & JohnsonGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$2.75B8.61$4.25 per share23.25$92.17 per share1.07GSKGSK$31.38B2.36$5.68 per share6.32$8.07 per share4.45JNJJohnson & Johnson$88.82B4.27$12.94 per share12.17$29.69 per share5.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech$1.01B-$3.00N/AN/AN/A-15.16%-2.35%-2.05%5/5/2025 (Estimated)GSKGSK$3.29B$1.5922.597.721.128.13%48.59%11.11%4/30/2025 (Estimated)JNJJohnson & Johnson$14.07B$6.6523.6714.222.5618.20%34.24%13.63%N/ALatest JNJ, BNTX, and GSK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025BNTXBioNTech-$2.68N/AN/AN/AN/AN/A4/30/2025Q1 2025GSKGSK$1.06N/AN/AN/A$7.52 billionN/A4/15/2025Q1 2025JNJJohnson & Johnson$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billion3/10/2025Q4 2024BNTXBioNTech$0.38$1.08+$0.70$1.15$1.24 billion$1.19 billion2/5/2025Q4 2024GSKGSK$0.44$0.59+$0.15$0.26$7.75 billionN/A1/22/2025Q4 2024JNJJohnson & Johnson$1.99$2.04+$0.05$1.41$22.44 billion$22.52 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTech$1.531.55%N/AN/A N/AGSKGSK$1.604.45%-17.33%100.63%N/AJNJJohnson & Johnson$4.963.15%+5.43%74.59%63 YearsLatest JNJ, BNTX, and GSK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/15/2025JNJJohnson & Johnsonquarterly$1.303.37%5/27/20255/27/20256/10/20252/5/2025GSKGSKquarterly$0.39324.2%2/21/20252/21/20254/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.017.337.21GSKGSK1.120.780.52JNJJohnson & Johnson0.431.110.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%GSKGSK15.74%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%GSKGSK10.00%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech3,080239.97 million193.71 millionOptionableGSKGSK90,1002.06 billion1.87 billionOptionableJNJJohnson & Johnson152,7002.41 billion2.40 billionOptionableJNJ, BNTX, and GSK HeadlinesRecent News About These CompaniesJohnson & Johnson (JNJ) Shows Strong Growth and Strategic ExpansionApril 18 at 2:07 AM | gurufocus.comLeerink Partnrs Expects Lower Earnings for Johnson & JohnsonApril 18 at 1:49 AM | americanbankingnews.comJohnson & Johnson (NYSE:JNJ) Trading 0.4% Higher After Better-Than-Expected EarningsApril 18 at 1:09 AM | americanbankingnews.comHow To Put $100 In Your Retirement Fund Each Month With Johnson & Johnson StockApril 17 at 10:47 PM | benzinga.comJohnson & Johnson Returns Epilepsy Drug Rights to Addex (ADXN)April 17 at 1:59 PM | gurufocus.comMorgan Stanley Forecasts Strong Price Appreciation for Johnson & Johnson (NYSE:JNJ) StockApril 17 at 12:17 PM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Earns "Outperform" Rating from Royal Bank of CanadaApril 17 at 12:17 PM | marketbeat.comJohnson & Johnson (JNJ): Among the Innovative Healthcare Stocks to Watch in 2025April 17 at 11:48 AM | insidermonkey.com3 High-Yield Dividend All-Stars to Buy Right NowApril 17 at 11:19 AM | 247wallst.comJohnson & Johnson (NYSE:JNJ) Trading Up 0.4% on Strong EarningsApril 17 at 11:16 AM | marketbeat.comJohnson & Johnson (JNJ): Among the Innovative Healthcare Stocks to Watch in 2025April 17 at 10:57 AM | finance.yahoo.comHere's How You Should Play JNJ Stock After Q1 Earnings BeatApril 17 at 9:05 AM | zacks.comThe Relief Rally Is Over: 4 Incredible Dividend Monarchs Are Our Safest Ideas NowApril 17 at 7:42 AM | 247wallst.comGreenwood Gearhart Inc. Trims Stock Position in Johnson & Johnson (NYSE:JNJ)April 17 at 7:29 AM | marketbeat.comMSH Capital Advisors LLC Takes Position in Johnson & Johnson (NYSE:JNJ)April 17 at 7:22 AM | marketbeat.comZacks Investment Management Reduces Holdings in Johnson & Johnson (NYSE:JNJ)April 17 at 7:19 AM | marketbeat.comNetflix stock has been nearly unscathed by Trump tariffs. Some think it could be Silicon Valley’s version of Johnson & JohnsonApril 17 at 7:13 AM | fortune.comJohnson & Johnson (NYSE:JNJ) Shares Sold by Marshall Wace LLPApril 17 at 7:01 AM | marketbeat.comNewEdge Advisors LLC Has $42.72 Million Stake in Johnson & Johnson (NYSE:JNJ)April 17 at 6:52 AM | marketbeat.comInsigneo Advisory Services LLC Trims Holdings in Johnson & Johnson (NYSE:JNJ)April 17 at 6:34 AM | marketbeat.comMain Street Financial Solutions LLC Cuts Stock Position in Johnson & Johnson (NYSE:JNJ)April 17 at 6:19 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?Are Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?3 Defense Stocks Set to Benefit From Increased Military SpendingBy Chris Markoch | March 20, 2025View 3 Defense Stocks Set to Benefit From Increased Military Spending3 Stocks Near 52-Week Lows With Strong Rebound PotentialBy Gabriel Osorio-Mazilli | March 31, 2025View 3 Stocks Near 52-Week Lows With Strong Rebound PotentialJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? By Chris Markoch | April 16, 2025View Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? JNJ, BNTX, and GSK Company DescriptionsBioNTech NASDAQ:BNTX$98.76 +0.51 (+0.52%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$98.77 +0.01 (+0.01%) As of 04/17/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.GSK NYSE:GSK$35.92 +0.55 (+1.54%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$35.74 -0.18 (-0.50%) As of 04/17/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.Johnson & Johnson NYSE:JNJ$157.42 +3.51 (+2.28%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$157.50 +0.08 (+0.05%) As of 04/17/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk Tariff-Resistant Abbott Laboratories on Track for New Highs Goldman Sachs Just Revealed What’s Next for Markets United Airlines Is in Reversal—If the Economy Doesn’t Stall Buy the Boeing Dip Even on Tariff and Bans? Spotify Stock Climbs as Its Growth Strategy Diversifies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
